Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (263)	12/12/2001 3:53:42 PM
From: scaram(o)uche	Respond to of 370

Jim: I haven't followed TAPET, but even with the VION bacteria that are LPS disabled, I would imagine that most express concern about systemic toxicity. When I say "concern", I'm again speaking from the context of "two years of no study" ignorance. I know enough to be careful, and too little to catch any upside given that my concern has no valid foundation. So..... ignore me. I've worked briefly with Dr. Vogelstein (a SBIR consultant while I was at PharMingen). Yup, he's bright. Not to mention just a tad accomplished. :-) Although the JHU stuff doesn't seem to acknowledge VION's work, I'm certain that it's acknowledged in the manuscript (which I should remember to look up when next in the library). Thanks for finding the JHU slant. Rick

To: Jim Oravetz who wrote (263)	1/3/2002 1:01:31 PM
From: Jim Oravetz	Read Replies (2) \| Respond to of 370

Missed this PR, Re: the Hopkins study vionpharm.com Looks like Vion has a better delivery vehicle. Jim

To: Jim Oravetz who wrote (263)	3/13/2002 1:05:57 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 370

Vion Pharma Will Formally Introduce New CFO Next Week DOW JONES NEWSWIRES NEW HAVEN, Conn. -- Vion Pharmaceuticals Inc. (VION) Chief Financial Officer Steve Koehler will leave the company for personal reasons. In a press release Wednesday, Vion said a replacement has been appointed, but a formal announcement will be made next week, at the request of the new chief financial officer's present company. Separately, Vion said it will present an update on the status of its clinical trial programs in a conference call scheduled for 11:00 a.m EST Wednesday. Vion said it's "pleased with the trends we are seeing in the clinical trials. We believe that for a company of our size to have four products (Triapine, SHP Prodrugs, TAPET and TAPET CD) in clinical trials, all with good revenue potential, is a major accomplishment." With a cash balance of almost $23 million at the end of 2001, Vion said it continues to manage cash "efficiently and effectively."